Table 1 Baseline Demographic and Medical Characteristics*
From: Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia
| Â | Study Population | |||
|---|---|---|---|---|
| Â | mITT | CE | ||
Characteristic | Tigecycline (n = 216) | Levofloxacin (n = 212) | Tigecycline (n = 144) | Levofloxacin (n = 136) |
Male, n (%) | 131 (61) | 133 (63) | 91 (63) | 87 (64) |
Race, n (%) | Â | Â | Â | Â |
   White | 189 (88) | 184 (87) | 129 (90) | 117 (86) |
   Black | 2 (<1) | 4 (2) | - | 3 (2) |
   Asian | 5 (2) | 7 (3) | 3 (2) | 7 (5) |
   Other | 20 (9) | 17 (8) | 12 (8) | 9 (7) |
Mean age ± SD, years (range) | 49.9 ± 18.1 (17--92) | 49.7 ± 17.4 (18--85) | 52.8 ± 16.9 (18--89) | 50.4 ± 17.0 (18--85) |
Fine Pneumonia Severity Score Index, n (%) | Â | Â | Â | Â |
   I | 32 (15) | 41 (19) | 18 (13) | 23 (17) |
   II | 79 (37) | 61 (29) | 49 (34) | 40 (29) |
   III | 59 (27) | 66 (31) | 40 (28) | 42 (31) |
   IV | 44 (20) | 42 (20) | 35 (24) | 30 (22) |
   V | 2 (<1) | 2 (<1) | 2 (1) | 1 (<1) |
Prior antibiotic failure, n (%) | 44 (20) | 55 (26) | 9 (6) | 15 (11) |
Presence of underlying medical conditions | Â | Â | Â | Â |
   COPD, n (%) | 14 (7) | 19 (9) | 10 (7) | 14 (10) |
   Diabetes mellitus, n (%) | 24 (11) | 25 (12) | 17 (12) | 16 (12) |
   Alcohol abuse, n (%) | 14 (7) | 10 (5) | 10 (7) | 7 (5) |
   Neoplastic disease, n (%) | - | 2 (<1) | - | 2 (2) |
   Liver disease, n (%) | 15 (7) | 8 (4) | 10 (7) | 4 (3) |
   Congestive heart disease, n (%) | 15 (7) | 15 (7) | 13 (9) | 10 (7) |
   Cerebrovascular disease, n (%) | 12 (6) | 17 (8) | 8 (6) | 13 (10) |